Cancel

Links to sites outside of takeda.com are provided as a resource to the audiences. Please note that Takeda is not responsible or liable for any third-party website and the website may not be appropriate for all audiences. 

To stay on the current website, select “Cancel”


Continue

You are leaving Takeda.com

Takeda - Global

EPD-3055 OneTrust Cookie

EPD-3519 Schema Script

EPD-2855 GTM Script

EPD-4037 Matomo Tag Manager

EPD-4268 Cookie Script Hack

Review FY2021 Takeda Pharmaceuticals financial results. Download quarterly presentations, statements, and databooks.

Fiscal Year 2021 Earnings Results | Takeda Investor Relations

# Quarterly Results FY2021 (April 2021-March 2022)



Divider Section

### Quarter 4



### Reference materials

*   [Clinical trial summary](https://assets-dam.takeda.com/raw/upload/v1675192593/legacy-dotcom/siteassets/system/investors/report/quarterlyannouncements/fy2021/clinical-trial-summary-may-2022.pdf) (updated May 11, 2022)

*   [Epidemiology data](https://assets-dam.takeda.com/raw/upload/v1675192597/legacy-dotcom/siteassets/system/investors/report/quarterlyannouncements/fy2021/qr2021_q4_epi-data.pdf) (updated May 11, 2022)



### Quarter 3



### Quarter 2



### Quarter 1



1.  Certain financial information in this press release and webcast, as applicable, is out-of-date as a result of a decision that Takeda received from the Irish Tax Appeals Commission related to the treatment of a break fee received by Shire plc in October 2014 from AbbVie Inc.  Please see Takeda’s August 2, 2021 [press release](https://www.takeda.com/newsroom/newsreleases/2021/takeda-receives-decision-by-the-irish-tax-appeals-commission-relating-to-tax-assessment-on-break-fee-shire-received-from-abbvie) for information related to the Irish Tax Appeals Commission’s decision and Takeda’s August 6, 2021 ****[press release ](https://www.takeda.com/newsroom/newsreleases/2021/takeda-updates-its-q1-fy2021-earnings-materials-to-reflect-impact-of-decision-by-the-irish-tax-appeals-commission-relating-to-tax-assessment-on-break-fee-shire-received-from-abbvie)for details of the revisions to its previously disclosed financial information.

2.  This document, which was originally published on July 30, 2021, was revised on August 6, 2021 as a result of a decision that Takeda received from the Irish Tax Appeals Commission.  Please see Takeda’s August 2, 2021 [press release ](https://www.takeda.com/newsroom/newsreleases/2021/takeda-receives-decision-by-the-irish-tax-appeals-commission-relating-to-tax-assessment-on-break-fee-shire-received-from-abbvie)for information related to the Irish Tax Appeals Commission’s decision and Takeda’s August 6, 2021 [press release ](https://www.takeda.com/newsroom/newsreleases/2021/takeda-updates-its-q1-fy2021-earnings-materials-to-reflect-impact-of-decision-by-the-irish-tax-appeals-commission-relating-to-tax-assessment-on-break-fee-shire-received-from-abbvie)for details of the revision.

3.  This document, which was originally filed with the Tokyo Stock Exchange on July 30, 2021, has been updated as a result of a decision that Takeda received from the Irish Tax Appeals Commission and re-filed with Tokyo Stock Exchange on August 6, 2021.  Please see Takeda’s August 2, 2021 [press release ](https://www.takeda.com/newsroom/newsreleases/2021/takeda-receives-decision-by-the-irish-tax-appeals-commission-relating-to-tax-assessment-on-break-fee-shire-received-from-abbvie)for information related to the Irish Tax Appeals Commission’s decision and Takeda’s August 6, 2021 [press release](https://www.takeda.com/newsroom/newsreleases/2021/takeda-updates-its-q1-fy2021-earnings-materials-to-reflect-impact-of-decision-by-the-irish-tax-appeals-commission-relating-to-tax-assessment-on-break-fee-shire-received-from-abbvie) for details of the revision.



* The English version of the Annual Securities Report/Quarterly Securities Report is provided as a reference material to assist foreign investors in understanding the Securities Report, which was filed with Japanese FSA (Financial Services Agency). We do not provide assurance about the accuracy, validity, or coverage of the English translation of this document, and if the description and explanation of this document differs from those of the Japanese Annual Securities Report/Quarterly Securities Report which was filed, the Securities Report in Japanese shall prevail.

## Archive



Quarterly Results FY2021 (April 2021-March 2022)

タケダの2021年度の決算情報をご覧ください。

2021年度決算情報 | IR資料 | 武田薬品

#2021年度 第2四半期 オーディオ


## アーカイブ



キャンセル 

外部のウェブサイトへのリンクは、参考として掲載しています。
なお、タケダは、外部のウェブサイトに関して責任を負いません。また、外部のウェブサイトは全てのユーザーにとって適切なものとは限りません。

このままタケダのウェブサイトをご覧になる場合は、「キャンセル」ボタンをクリックしてください。


2021年度決算情報 | IR資料 | 武田薬品

2021年度 第2四半期 オーディオ

2021年度第2四半期オーディオ